Jundishapur Journal of Chronic Disease Care

Published by: Kowsar

Coexistence of Crohn’s Disease and Hodgkin’s Lymphoma in a Young Man with Rectorrhagia

Ahmad Hormati 1 , * , Mohammad Reza Ghadir 2 , Seyed Saeed Sarkeshikian 1 , Abolfazle Iranikhah 3 , Faezeh Alemi 4 and Mahdieh Ghoddoosi 5
Authors Information
1 Assistant Professor of Gastroenterology, Gastroenterology and Hepatology Disease Research Center, Qom University of Medical Sciences, Qom, Iran
2 Associated Professor of Gastroenterology, Gastroenterology and Hepatology Disease Research Center, Qom University of Medical Sciences, Qom, Iran
3 Assistant Professor of Pediatric Gastroenterology, Gastroenterology and Hepatology Disease Research Center, Qom University of Medical Sciences, Qom, Iran
4 General Practitioner, Gastroenterology and Hepatology Disease Research Center, Qom University of Medical Sciences, Qom, Iran
5 Pathologist, Qom University of Medical Sciences, Qom, Iran
Article information
  • Jundishapur Journal of Chronic Disease Care: April 2017, 6 (2); e42794
  • Published Online: February 27, 2017
  • Article Type: Case Report
  • Received: December 6, 2016
  • Revised: January 16, 2017
  • Accepted: January 22, 2017
  • DOI: 10.5812/jjcdc.42794

To Cite: Hormati A, Ghadir M R, Sarkeshikian S S, Iranikhah A, Alemi F, et al. Coexistence of Crohn’s Disease and Hodgkin’s Lymphoma in a Young Man with Rectorrhagia, Jundishapur J Chronic Dis Care. 2017 ; 6(2):e42794. doi: 10.5812/jjcdc.42794.

Abstract
Copyright © 2017, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Introduction
2. Case Presentation
3. Discussion
Acknowledgements
Footnote
References
  • 1. Zhang YZ, Li YY. Inflammatory bowel disease: pathogenesis. World J Gastroenterol. 2014; 20(1): 91-9[DOI][PubMed]
  • 2. Salem M, Ammitzboell M, Nys K, Seidelin JB, Nielsen OH. ATG16L1: A multifunctional susceptibility factor in Crohn disease. Autophagy. 2015; 11(4): 585-94[DOI][PubMed]
  • 3. Das D, Gupta B, Saha M. Metastatic Vulvar Crohn's Disease-A Rare Case Report and Short Review of Literature. Indian J Dermatol. 2016; 61(1): 70-4[DOI][PubMed]
  • 4. Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009; 7(8): 874-81[DOI][PubMed]
  • 5. Parian A, Lazarev M. Who and how to screen for cancer in at-risk inflammatory bowel disease patients. Expert Rev Gastroenterol Hepatol. 2015; 9(6): 731-46[DOI][PubMed]
  • 6. Sifuentes H, Kane S. Monitoring for Extra-Intestinal Cancers in IBD. Curr Gastroenterol Rep. 2015; 17(11): 42[DOI][PubMed]
  • 7. Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005; 54(8): 1121-5[DOI][PubMed]
  • 8. Lakatos PL, Lovasz BD, David G, Pandur T, Erdelyi Z, Mester G, et al. The risk of lymphoma and immunomodulators in patients with inflammatory bowel diseases: results from a population-based cohort in Eastern Europe. J Crohns Colitis. 2013; 7(5): 385-91[DOI][PubMed]
  • 9. Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006; 54(3): 692-701[DOI][PubMed]
  • 10. Biancone L, Onali S, Petruzziello C, Calabrese E, Pallone F. Cancer and immunomodulators in inflammatory bowel diseases. Inflamm Bowel Dis. 2015; 21(3): 674-98[DOI][PubMed]
  • 11. Nissen LH, Nagtegaal ID, de Jong DJ, Kievit W, Derikx LA, Groenen PJ, et al. Epstein-Barr virus in inflammatory bowel disease: the spectrum of intestinal lymphoproliferative disorders. J Crohns Colitis. 2015; 9(5): 398-403[DOI][PubMed]
  • 12. Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lemann M, Cosnes J, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009; 374(9701): 1617-25[DOI][PubMed]
  • 13. Vos AC, Bakkal N, Minnee RC, Casparie MK, de Jong DJ, Dijkstra G, et al. Risk of malignant lymphoma in patients with inflammatory bowel diseases: a Dutch nationwide study. Inflamm Bowel Dis. 2011; 17(9): 1837-45[DOI][PubMed]
  • 14. Ghadir MR, Bagheri M, Vahedi H, Ebrahimi Daryani N, Malekzadeh R, Hormati A, et al. Nonadherence to Medication in Inflammatory Bowel Disease: Rate and Reasons. Middle East J Dig Dis. 2016; 8(2): 116-21[DOI][PubMed]
  • 15. Yabe M, Medeiros LJ, Daneshbod Y, Davanlou M, Bueso-Ramos CE, Moran EJ, et al. Hepatosplenic T-cell lymphoma arising in patients with immunodysregulatory disorders: a study of 7 patients who did not receive tumor necrosis factor-alpha inhibitor therapy and literature review. Ann Diagn Pathol. 2017; 26: 16-22[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments